Get the Stockscreener App
1.21
4.72%
-0.06
After Hours:
1.22
0.01
+0.83%
Biovie Inc stock is traded at $1.21, with a volume of 226.22K.
It is down -4.72% in the last 24 hours and down -16.55% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.27
Open:
$1.27
24h Volume:
226.22K
Relative Volume:
2.06
Market Cap:
$9.12M
Revenue:
-
Net Income/Loss:
$-25.56M
P/E Ratio:
-0.2327
EPS:
-5.2
Net Cash Flow:
$-19.35M
1W Performance:
-14.18%
1M Performance:
-16.55%
6M Performance:
+17.48%
1Y Performance:
-46.22%
1-Day Range:
$1.155
$1.306
1-Week Range:
$1.155
$1.46
52-Week Range:
$0.62
$9.56
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.21 | 9.57M | 0 | -25.56M | -19.35M | -5.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - The Malaysian Reserve
BioVie (NASDAQ:BIVI) Trading Down 5.8% – What’s Next? - Defense World
BioVie Inc Stock Analysis and ForecastEconomic Impact on Stocks & Free Real-Time Stock Market Data - earlytimes.in
Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Daily Commercial
BioVie advances lead drug candidatesICYMI - Proactive financial news
Breakout Zone: Will BioVie Inc. stock outperform Dow Jones indexJobs Report & Reliable Price Breakout Alerts - Улправда
Why retail investors pile into BioVie Inc. stockJuly 2025 Technicals & Reliable Entry Point Alerts - Улправда
What Wall Street predicts for BioVie Inc. stock priceMarket Performance Summary & Stepwise Swing Trade Plans - Улправда
Aug Movers: How BioVie Inc. stock compares to industry benchmarksJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - Улправда
How BioVie Inc. stock compares to industry benchmarks2025 EndofYear Setup & Precise Buy Zone Identification - ulpravda.ru
Why BioVie Inc. stock is rated strong buyJuly 2025 Retail & Reliable Entry Point Trade Alerts - DonanımHaber
Market Fear: Will BioVie Inc. stock outperform Dow Jones index2025 Trading Recap & High Accuracy Swing Trade Signals - Улправда
Is BioVie Inc. stock dividend yield sustainableWeekly Risk Summary & Weekly Return Optimization Alerts - Улправда
Fund Flows: What momentum indicators show for BioVie Inc. stockJuly 2025 Outlook & Daily Chart Pattern Signal Reports - Улправда
What momentum indicators show for BioVie Inc. stockQuarterly Performance Summary & Technical Confirmation Trade Alerts - Улправда
BioVie advances Parkinson’s, long COVID, and liver disease programs ahead of 2026 - Proactive financial news
What makes BioVie (BIVI) a new buy stock - MSN
What Makes BioVie (BIVI) a New Buy Stock - sharewise.com
Transcript : BioVie Inc.Special Call - marketscreener.com
New to The Street Broadcasts Tonight on Bloomberg at 6:30 PM EST Featuring Roadzen, BioVie, and TY J Young Wealth - The Florida Times-Union
Breakout Watch: How BioVie Inc. stock compares to industry benchmarksPortfolio Performance Summary & Safe Capital Growth Trade Ideas - BỘ NỘI VỤ
Can BioVie Inc. stock sustain institutional interestJuly 2025 Review & Low Drawdown Trading Strategies - Newser
BioVie Inc. (BIVI) -5.7% in After-hours: Stock Declines Amid Routine Trading Conditions - Stocks Telegraph
BioVie (NASDAQ:BIVI) Shares Up 0.3% – Here’s What Happened - Defense World
BIVI SEC FilingsBiovie Inc 10-K, 10-Q, 8-K Forms - Stock Titan
[S-8] BIOVIE INC. Employee Benefit Plan Registration | BIVI SEC FilingForm S-8 - Stock Titan
BIVIW Insider Trading - Quiver Quantitative
BIVIW | BioVie Inc. Warrant Stock Data, Price & News - Quiver Quantitative
BioVie Inc. (BIVI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What drives BioVie Inc stock pricePrice Support Zones & Free Record-Breaking Gains - earlytimes.in
What catalysts could drive BioVie Inc. stock higherMarket Performance Summary & Consistent Growth Stock Picks - newser.com
Biotech Stocks Swing After Hours: Delcath Rises On Buyback, BioVie And Cassava Rebound - Nasdaq
Will BioVie Inc. stock outperform Nasdaq index2025 Market Overview & Daily Oversold Bounce Ideas - newser.com
How BioVie Inc. stock performs in stagflation2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com
Is BioVie Inc. stock safe for conservative investorsJuly 2025 Decliners & Expert Verified Stock Movement Alerts - newser.com
How currency fluctuations impact BioVie Inc. stockOil Prices & Weekly Watchlist of Top Performers - newser.com
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9 - The Manila Times
[EFFECT] BIOVIE INC. SEC Filing - Stock Titan
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):